Finally, the idea of intracellular S1P fluctuations affecting PP2A activity may be relevant to a variety of human diseases beyond diabetes and could be exploited pharmacologically by already known drugs intervening in S1P homeostasis. This evidence concerns the gene PTPA and diabetes mellitus.